(Bloomberg) — Generic versions of Novo Nordisk A/S’s hit shots Ozempic and Wegovy could be sold for under $3 a month, a new study showed, underscoring their potential to unlock global access to powerful weight-loss drugs. Read More
Source link
(Bloomberg) — Generic versions of Novo Nordisk A/S’s hit shots Ozempic and Wegovy could be sold for under $3 a month, a new study showed, underscoring their potential to unlock global access to powerful weight-loss drugs. Read More
Source link